Michael Hennig
CEO
leadXpro AG,Switzerland
Switzerland
Biography
Co-founder and CEO of leadXpro AG, a spin-out of the Paul Scherrer Institute (ETH domain, Switzerland) dedicated to discovery of new therapeutics using structure based drug discovery with a focus on membrane protein targets,20 years at Roche research from 1995 to 2015, Global Head and Principle Leader of discovery technologies with responsibility for structure based drug discovery, protein science, assay development and HTS, corporate compound library, stem cell platform,Guest Professor at the University of Basel in structural biology, author of >75 paper and lecturer at conferences, 8 patents in areas of technology, discovery and formulation of drug substances,Study of physics, biochemistry, PhD in structural biology at EMBL Hamburg & Charité Berlin, Germany, postdoc at Biozentrum, University of Basel, Switzerland
Research Interest
Discovery of new therapeutics using structure based drug discovery with a focus on membrane protein targets